Cicloral versus neoral: A bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral

Transplantation Proceedings

Volumn 36, Issue 10, 2004, Pages 3234-3238

  Kees, F ^a   Mair, G ^a   Dittmar, M ^a   Bucher, M ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GENERIC DRUG; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID DIET; MALE; MICROEMULSION; PRIORITY JOURNAL; BIOAVAILABILITY; BLOOD; FAT INTAKE; PHARMACOKINETICS; REFERENCE VALUE;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYCLOSPORINE; DIETARY FATS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 21244439163     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.10.018     Document Type: Article

References (20)

1. Fleisher D, Li C, Zhou Y, et al: Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233, 1999
2. Langford CA, Klippel JH, Balow JE, et al: Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann Intern Med 128: 1021, 1998
3. Langford CA, Klippel JH, Balow JE, et al: Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129:49, 1998
4. Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11:107, 1986
5. Gupta SK, Manfro RC, Tomlanovich SJ, et al: Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 30:643, 1990
6. Mueller EA, Kovarik JM, van Bree JB, et al: Influence of a fat-rich meal on the pharmacokinetics of cyclosporine in a crossover comparison with the market formulation. Pharm Res 11:151, 1994
7. Mueller EA, Niese D, Mellein B: Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships. Transplant Proc 30:1694, 1998
8. Koehler J, Kuehnel T, Kees F, et al: Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine A in rats. Drug Metab Dis 30:658, 2002
9. FDA, Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies, Dec 2002. Available at: http://www. fda.gopv/cder/ guidance/5194fnl.pdf
10. Brozmanova H, Grundmann M, Safarcik K, et al: High-performance liquid chromatographic method for therapeutic drug monitoring of cyclosporine A and its two metabolites in renal transplant patients. J Chromatogr B 749:93, 2000
11. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, Committee for Proprietary Medicinal Products: Commission of the European Communities, London, England, July, 26, 2001
12. Steinijans VW, Hauschke D: International harmonization on regulatory bioequivalence requirements. Clin Res Reg Affairs. 10:203, 1993
13. Klauser RM, Irschik H, Kletzimayr J, et al: Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter? Transplant Proc 29:3137, 1997
14. Durlik M, Rauch C, Thyroff-Friesinger U, et al: Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations. Transplant Proc 35:1304, 2003
15. Melander A: Influence of food on the bioavailability of drugs. Clin Pharmacokinet 3:337, 1978
16. Christians U, Sewing KF: Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 28:547, 1995
17. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinetics 24:472, 1993
18. Steimer W: Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 45:37, 1999
19. First MR, Alloway R, Schroeder TJ: Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. Clin Transplant 12:518, 1998
20. Park MS, Yu NC, Kim YS, et al: Bioequivalence study of Cipol-N (cyclosporine microemulsion preparation) in healthy adults. Transplant Proc 30:3541, 1998